International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationsFIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy
Introduction
Definitive radiation therapy is widely accepted as the treatment of choice for patients with FIGO Stage IIIB carcinoma of the cervix. Investigators have reported survival rates of between 30% and 50% for patients treated with radiation therapy alone 1, 2, 3, 4, 5. However, while Stage IIIB carcinomas metastasize to extrapelvic sites more often than do earlier stage tumors, pelvic recurrence continues to be a major cause of morbidity and mortality in treated patients. Clinicians continue to disagree about the relative importance of external beam irradiation (EBRT), which can be used to treat all of the pelvic tissues, and intracavitary radiation therapy (ICRT), which gives a very high dose of radiation to the central tumor, but delivers a lower dose to disease near the pelvic wall. Some clinicians have tried to increase the dose of radiation to the paracervical tissues and pelvic wall, usually at the expense of some decrease in the central dose, by substituting interstitial brachytherapy for the more traditional ICRT. Investigators have also tried a number of experimental treatments designed to enhance the response of tumors to radiation therapy: neutrons, hyperbaric oxygen, radiation sensitizers, and concurrent or neoadjuvant chemotherapy delivered intravenously or intraarterially. None of these approaches has yet been proven to improve results over treatment with radiation alone, although the role of concurrent chemoradiation is being actively studied.
At The University of Texas M. D. Anderson Cancer Center, the approach to treating Stage III disease has evolved significantly over the past several decades. Concern that ICRT may not adequately address tumor fixed to the pelvic wall led to the use of progressively higher doses of EBRT to the central pelvis after a high-energy (25 MV) betatron beam became available in the late 1950s. This trend was gradually reversed in the 1980s and 1990s, when greater emphasis was placed on the intracavitary component of treatment for these advanced lesions.
This retrospective review of the experience at M. D. Anderson Cancer Center was performed to explore the influence of changes in treatment policy on the results of radiation therapy and to refine our understanding of the influence of tumor characteristics on the outcome of patients with FIGO Stage IIIB disease.
Section snippets
Patients
The medical records, including clinical notes and tumor diagrams, of all patients treated with radiation therapy for squamous cell carcinoma of the uterine cervix between January 1960 and December 1993 at M. D. Anderson were reviewed retrospectively. Patients with a history of prior hysterectomy or supracervical hysterectomy and those who presented with recurrent disease were excluded. Of the remaining 4,843 patients, a total of 1,096 were treated with radiation therapy for tumors that met
Patient characteristics
The median age at diagnosis of the 1,096 patients in this study was 54 years (range 19–99 years). In contrast, the median age of patients treated with radiation for Stage IB disease during this period was 47 years. Nine hundred thirty-seven (85%) of 1,096 patients presented with abnormal vaginal bleeding. Three hundred twenty-six (30%) had an initial hemoglobin level of < 10 g/dl. Two hundred fifty-four patients (23%) reported an abnormal discharge, and 334 (30%) complained of pain. Thirty-one
Discussion
The treatment of FIGO Stage IIIB carcinoma of the cervix poses special problems for the radiation oncologist. The tumor volume is usually large, and the likelihood of regional metastasis is great. As a result, clinicians tend to emphasize the role of EBRT more than they would for earlier stage disease, arguing that an emphasis on ICRT results in relative undertreatment of tumor extending toward or involving the pelvic sidewall. However, the results of this study provide convincing evidence that
References (44)
- et al.
Carcinoma of the intact uterine cervix treated with radiotherapy aloneA French Cooperative Study: Update and multivariate analysis of prognostics factors
Int J Radiat Oncol Biol Phys
(1997) - et al.
Prognostic factors in patients with cervix cancer treated by radiation therapyResults of a multiple regression analysis
Radiother Oncol
(1995) - et al.
The effect of volume of disease in patients with carcinoma of the uterine cervix
Int J Radiat Oncol Biol Phys
(1991) - et al.
Tumor and treatment factors improving outcome in stage III-B cervix cancer
Int J Radiat Oncol Biol Phys
(1991) - et al.
Whole pelvis megavoltage irradiation with single doses of 1000 rad to palliate advanced gynecologic cancers
Int J Radiat Oncol Biol Phys
(1979) - et al.
Neutron therapy in cervical cancerResults of a phase III RTOG study
Int J Radiat Oncol Biol Phys
(1988) - et al.
Treatment of locally advanced cervical cancer with concurrent radiation and intra-arterial chemotherapy
Gynecol Oncol
(1995) - et al.
Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix
Int J Radiat Oncol Biol Phys
(1995) - et al.
The effect of treatment duration in the local control of cervix cancer
Radiother Oncol
(1992) - et al.
The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiationA Patterns-of-Care Study
Int J Radiat Oncol Biol Phys
(1993)
The adverse effect of treatment prolongation in cervical carcinoma
Int J Radiat Oncol Biol Phys
Stage III carcinoma of cervix. The importance of increasing age and extent of parametrial involvement
Radiother Oncol
Long term results of radium therapy in cervical cancer
Int J Radiat Oncol Biol Phys
Heuristically derived tumor burden score as a prognostic factor for stage IIIB carcinoma of the cervix
Int J Radiat Oncol Biol Phys
The clinical implications of hydronephrosis and the level of ureteral obstruction in stage IIIB cervical cancer
Int J Radiat Oncol Biol Phys
The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix
Int J Radiat Oncol Biol Phys
Radiotherapy alone in carcinoma of the intact uterine cervix according to G. H. Fletcher guidelinesA French cooperative study of 1383 cases
Int J Radiat Oncol Biol Phys
Combination of external beam irradiation and multiple-site perineal applicator (MUPIT) for treatment of locally advanced or recurrent prostatic, anorectal, and gynecologic malignancies
Int J Radiat Oncol Biol Phys
Parametrial interstitial brachytherapy for advanced or recurrent pelvic malignancyThe Harvard/Stanford experience
Gynecol Oncol
A comparison of intracavitary versus interstitial irradiation in the treatment of cervical cancer
Gynecol Oncol
Customized gynecologic interstitial implantsCT-based planning, dose evaluation, and optimization aided by laparotomy
Int J Radiat Oncol Biol Phys
The significance of anemia in clinical radiation therapy
Int J Radiat Oncol Biol Phys
Cited by (258)
A Dosimetric Correlation Between Radiation Dose to Bone and Reduction of Hemoglobin Levels After Radiation Therapy for Prostate Cancer
2024, International Journal of Radiation Oncology Biology PhysicsESGO/ESTRO quality indicators for radiation therapy of cervical cancer
2023, Radiotherapy and OncologyThe Kelowna template for combined intracavitary and interstitial brachytherapy for gynecologic malignancies: Design, application, treatment planning, dosimetric and treatment outcomes
2022, BrachytherapyCitation Excerpt :Brachytherapy (BT) is an essential element in the treatment of locally advanced or recurrent gynecologic malignancies that allows for delivery of high-doses of curative radiation therapy while limiting doses to normal tissue. Many studies have reported increased local tumor control, better outcomes, and decreased normal tissue toxicities when BT is involved in the treatment course (1–3). Accordingly, prospective trials have compared 2D and 3D BT, and 3D BT improves local control rates and limits toxicities (4,5).